GMP plasmid CMO VGXI appoints Dorothy Peterson as Chief Operating Officer, overseeing all aspects of the Texas-based production facility.
The Woodlands, TX – April 25, 2018 – VGXI is pleased to announce that Vice President of Operations Dorothy Peterson has been appointed Chief Operating Officer. Peterson joined VGXI in 2007 as the Director of Quality and was promoted to VP of Operations in 2011. During her tenure she has played a critical role in implementing VGXI’s Quality System, emphasizing continuous improvement and ensuring compliance with cGMP regulations across departments.
“Under Dorothy’s leadership, VGXI has seen sustained growth both in our client base and in the breadth and quality of services provided to our customers,” said VGXI’s President and CEO Young Park. “She is also clearly dedicated to the employees, promoting a culture of teamwork and commitment within VGXI. This promotion is a recognition of the responsibilities Dorothy has undertaken for several years, and of her tremendous contributions to the company. ”
“VGXI has built a reputation within the industry of providing the highest quality plasmid DNA products and services,” said Peterson. “I am excited to be a part of this team and to continue to support the success of our clients as they develop the next generation of therapies.”
Prior to VGXI, Peterson has more than 20 years of industry experience across various quality and operational roles. In particular as VP of Operations at Qualigen, Inc. she successfully submitted several 510(k) applications and led the company through multiple regulatory agency audits. Ms. Peterson received her Bachelor of Science in Biology from Sam Houston State University in Huntsville, Texas.
With over 15 years of experience, VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.
Cautionary Factors That May Affect Future Results
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
View the release on PRWeb: http://www.prweb.com/releases/2018/04/prweb15437405.htm
Media Contact: Christy Franco, PhD Manager, Business Development Email P: 281-466-3790